SG Americas Securities LLC cut its stake in Array BioPharma Inc. (NASDAQ:ARRY) by 55.4% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 17,851 shares of the biopharmaceutical company’s stock after selling 22,136 shares during the period. SG Americas Securities LLC’s holdings in Array BioPharma were worth $149,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Fisher Asset Management LLC boosted its position in shares of Array BioPharma by 72.0% in the second quarter. Fisher Asset Management LLC now owns 134,180 shares of the biopharmaceutical company’s stock worth $1,123,000 after acquiring an additional 56,166 shares during the last quarter. Spark Investment Management LLC boosted its position in shares of Array BioPharma by 30.9% in the first quarter. Spark Investment Management LLC now owns 343,900 shares of the biopharmaceutical company’s stock worth $3,074,000 after acquiring an additional 81,200 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Array BioPharma in the first quarter worth approximately $303,000. KCG Holdings Inc. boosted its position in shares of Array BioPharma by 15.5% in the first quarter. KCG Holdings Inc. now owns 26,638 shares of the biopharmaceutical company’s stock worth $238,000 after acquiring an additional 3,577 shares during the last quarter. Finally, TD Asset Management Inc. boosted its position in shares of Array BioPharma by 4.2% in the first quarter. TD Asset Management Inc. now owns 112,368 shares of the biopharmaceutical company’s stock worth $1,005,000 after acquiring an additional 4,500 shares during the last quarter. 97.59% of the stock is currently owned by institutional investors and hedge funds.

WARNING: This article was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/09/24/array-biopharma-inc-arry-shares-sold-by-sg-americas-securities-llc.html.

Array BioPharma Inc. (ARRY) opened at 11.32 on Friday. The firm’s 50-day moving average is $9.34 and its 200-day moving average is $8.78. Array BioPharma Inc. has a 12 month low of $3.45 and a 12 month high of $13.40. The firm’s market capitalization is $1.94 billion.

Array BioPharma (NASDAQ:ARRY) last announced its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.17) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.04. The business had revenue of $33.80 million during the quarter, compared to analysts’ expectations of $28.64 million. Array BioPharma had a negative return on equity of 1,187.18% and a negative net margin of 77.44%. The firm’s quarterly revenue was down 21.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.17) EPS. On average, equities research analysts expect that Array BioPharma Inc. will post ($0.99) EPS for the current year.

ARRY has been the topic of several research analyst reports. BidaskClub raised shares of Array BioPharma from a “strong sell” rating to a “sell” rating in a research report on Friday, August 25th. ValuEngine raised shares of Array BioPharma from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Stifel Nicolaus reissued a “buy” rating and issued a $13.00 target price on shares of Array BioPharma in a research report on Thursday, August 10th. Cantor Fitzgerald reissued a “buy” rating and issued a $13.00 target price on shares of Array BioPharma in a research report on Tuesday, July 18th. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $9.00 target price on shares of Array BioPharma in a research report on Tuesday, September 12th. One analyst has rated the stock with a sell rating, three have given a hold rating and seven have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $13.10.

Array BioPharma Company Profile

Array BioPharma Inc is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company’s programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC).

Want to see what other hedge funds are holding ARRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Array BioPharma Inc. (NASDAQ:ARRY).

Institutional Ownership by Quarter for Array BioPharma (NASDAQ:ARRY)

Receive News & Stock Ratings for Array BioPharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Array BioPharma Inc. and related stocks with our FREE daily email newsletter.